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ABSTRACT
Among the current treatments available for acne vulgaris, many widely practiced options lack support 
from studies at the best level of scientific evidence. The aim of this narrative review was to present the 
very latest information on topical and systemic treatments for acne vulgaris. Information from systematic 
reviews and well-designed clinical trials, obtained through a systematic search of the major medical da-
tabases, is emphasized. There are important issues regarding the clinical management of acne that still 
lack consistent grounding in scientific evidence. Among these are the optimum dose and duration of 
treatment with oral antibiotics that can be given without inducing bacterial resistance, and the safety of 
oral isotretinoin.  
RESUMO
Na terapêutica atual da acne vulgar, muitas opções amplamente praticadas carecem de respaldo em es-
tudos de melhor nível de evidência científica. O objetivo desta revisão narrativa é apresentar o que há de 
mais recente no tratamento tópico e sistêmico da acne vulgar. São enfatizadas as informações de revisões 
sistemáticas e de ensaios clínicos com bom desenho metodológico, obtidas a partir de busca sistematiza-
da nas principais bases de dados em medicina. Há importantes questões referentes à conduta clínica dian-
te da acne que ainda requerem embasamento em evidências científicas consistentes, entre elas a dose e 
a duração ideais do tratamento com antibióticos orais, sem que ocorra indução de resistência bacteriana, 
e a segurança da isotretinoína oral.
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INTRODUCTION
In cases of acne vulgaris, the initial therapeutic approach should 
take into account the severity of the clinical lesion type, i.e. whether 
there is predominance of inflammatory lesions or comedones. 
Classifying acne vulgaris according to the severity of the lesions 
into mild (papulopustular or comedonal), moderate (papulopus-
tular or nodular) and severe (nodulocystic or conglobate) is a use-
ful method for determining the most appropriate therapy, and this 
has been adopted in the treatment algorithms of the most recent 
international guidelines.1-5 Many widely practiced dermatological 
treatments lack support from studies providing high-level scien-
tific evidence. The United States Institute of Medicine places com-
parative research into the effectiveness of acne treatment among 
the top 100 scientific priorities in that area in the country.6
OBJECTIVES
The aim of this narrative review was to present the very latest good 
quality scientific evidence regarding topical and systemic treat-
ments for acne vulgaris. Preference has been given to information 
from systematic reviews and well-designed, controlled and ran-
domized clinical trials.
METHODS
A systematic search was conducted in the major databases, for studies 
relating to treatment of acne between the years 2001 and 2011, using 
health descriptors or terms relating to the subject matter (Table 1).
RESULTS AND DISCUSSION
In clinical practice, topical drugs have been shown to be effective for 
treating mild acne alone (except antibiotics) or in association with 
each other and/or with systemic medications. Several topical treat-
ment options, with different modes of action, are available for acne. 
Although they are more effective than placebo in cases of mild acne, 
there is still no single initial or maintenance topical treatment strat-
egy that is well validated by consistent scientific evidence.3-6 
Benzoyl peroxide (BPO) is used for treating moderate and 
severe forms of acne alone or, preferably, in fixed or sequential 
combinations with topical retinoids, azelaic acid and topical or 
systemic antibiotics.1,2,5 It is also used for women with moder-
ate to severe acne who are undergoing systemic hormonal anti-
androgen therapy.5 It can be given as monotherapy at the outset 
of treatment for mild, papulopustular acne. In such cases, this 
treatment strategy appears as one of the first-line options in cur-
rent British and German guidelines. The basis for this recommen-
dation is the lower cost and longer track record of BPO regarding 
its safety and efficacy, in comparison with topical retinoids.2,5-8 
BPO is an over-the-counter preparation. Its primary mecha-
nism of action is antimicrobial activity, which reduces colonization 
of hair follicles by Propionibacterium acnes, while it also discreetly 
works to reduce inflammation and follicular hyperkeratinization.5,6 
Unlike long-term antibiotic therapy, use of BPO does not induce 
bacterial resistance.1,5 Monotherapy with BPO has been shown to be 
as effective as an association of BPO with topical or oral antibiotics.9 
In 2010, Seidler and Kimball conducted a meta-analysis in which 
they compared the efficacy of 5% BPO, 1% to 1.2% clindamycin, 5% 
BPO with salicylic acid, and a combination of BPO and clindamy-
cin. The results showed that combinations of BPO were slightly more 
efficacious than use of this drug alone. While the difference was sta-
tistically significant, it is unlikely to be clinically important.10 Lower 
concentrations of BPO are recommended, as they produce less local 
irritation, which is the main adverse effect of medication. 
Following a systematic review, Fakhouri et al. concluded that 
the efficacy of BPO is similar at concentrations of 2.5%, 5% and 
10% and can be increased by addition of vitamin E and tertiary 
amines to the formulation, as well as by associating it with topical 
retinoids. According to these authors, new mechanisms for drug 
release have enhanced tolerability without decreasing efficacy.8,11 
Retinoids are vitamin A derivatives that prevent formation of 
comedones by normalizing scaling of the follicular epithelium. 
They also have some anti-inflammatory action. Retinoids are 
contraindicated in pregnant women, and women with childbear-
ing potential should use effective contraception simultaneously 
with treatment using these drugs. The main retinoids used topi-
cally for treating acne are: tretinoin, adapalene and tazarotene. 
The last of these is not currently available in Brazil.6,12 
Topical retinoids are indicated for use alone in cases of mild 
acne (comedonal or papulopustular) and in maintenance treatment 
once the disease has been controlled. In moderate and severe forms, 
topical retinoids are used in fixed or sequential combinations with 
BPO, azelaic acid, and/or topical or systemic antibiotics. They are 
also recommended for women with moderate to severe acne who 
are undergoing systemic hormonal anti-androgen treatment.5 
Several randomized controlled trials (RCTs) that compared 
topical retinoids with placebo have demonstrated their efficacy and 
Table 1. Systematic search for evidence on the treatment of acne vulgaris, performed on August 5, 2012
Database Search strategy Initial results
Studies selected for citation in the review
Systematic reviews Randomized controlled trials
PubMed “Acne Vulgaris” [Mesh] 2,915 17 (of 113) 6 (of 305)
Cochrane Library “Acne Vulgaris” [Mesh] 737 8 (of 21) 6 (of 705)
Lilacs mh: “acne vulgar” 271 0 (of 0) 0 (of 8)
Embase ‘acne vulgaris’/exp 2,064 9 (of 39) 6 (of 212)
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tolerability. However, more studies are needed in order to compare 
the various topical retinoids with each other and in combinations 
with other drugs that are used to treat acne.6 In general, all topical 
retinoids are effective in reducing the number of comedones and 
inflammatory lesions by about 40% to 70%. Data from RCTs sug-
gest that at higher concentrations, topical retinoids are more effi-
cacious but provide a greater risk of irritation. Adapalene seems to 
have less potential for causing irritation and to be better tolerated 
than tretinoin and tazarotene, while tazarotene seems more effica-
cious.12 In 1998, Cunliffe et al. conducted a meta-analysis on five 
multicenter investigator-blinded RCTs, which compared the effi-
cacy of 0.1% adapalene gel with 0.05% tretinoin gel and demon-
strated that adapalene produces a better therapeutic response with 
lower incidence of skin irritation.13 
A systematic review investigated whether the use of topical 
retinoids can cause temporary paradoxical worsening of lesions at 
baseline, which was a dogma hitherto widespread among North 
American dermatologists. The authors analyzed eight studies 
that found no evidence of worsening and only one study that sug-
gested a slight deterioration of the clinical condition of acne dur-
ing early treatment. They confirmed that topical retinoids cause 
skin irritation, but that good tolerance to the treatment develops 
over the first two to three months of treatment.11,14,15 
The topical antibiotics most commonly used to treat acne are 
clindamycin and erythromycin. These improve acne by suppress-
ing proliferation of Propionibacterium acne bacteria in the affected 
hair follicles, thus reducing local inflammation.6,12 In cases of acne, 
monotherapy with topical antibiotics is contraindicated due to the 
possibility of inducing bacterial resistance, which is related to wors-
ened therapeutic responses and relatively slow onset of action com-
pared with other antimicrobial regimens used in treating acne.1,4,9,12 
In a systematic review carried out in 2008, Simonart and 
Draimax analyzed RCTs on therapeutic interventions for acne. 
They concluded that there had been a gradual decrease in efficacy 
of erythromycin over the previous years, which was probably related 
to the emergence of resistant strains of Propionibacterium acnes.16 
Topical antibiotics, always in combination with topical reti-
noids, BPO or azelaic acid, are recommended for treatment of 
mild or moderate acne. They can also be used combined with 
systemic hormonal anti-androgen treatment in cases of mod-
erate acne in women.5 Erythema, scaling, dryness and burning 
sensation may occur during treatment with topical antibiotics.3 
Among the main contraindications and limitations to their use 
are pregnancy and breastfeeding for topical clindamycin and the 
risk of hepatotoxicity for erythromycin when applied to larger 
areas of skin among patients with abnormal liver function.5 
Salicylic acid has been used for many years for treating acne 
and is present in several topical pharmaceutical preparations 
currently available for sale without prescription. Its action is 
exfoliative and comedolytic, but there is no consistent evidence 
that corroborates its routine use in preference to any other topi-
cal treatment. With regard to effectiveness, it is inferior to topical 
retinoids and is only recommended for patients who may not tol-
erate the irritation resulting from the action of retinoids.4,6 
There are still some limitations in relation to the quality of 
the available evidence regarding the use of certain topical agents 
for management of acne, including sulfur, resorcinol, sodium 
sulfacetamide, aluminum chloride and zinc.4,6 
Azelaic acid mainly presents comedolytic, antibacterial and 
mildly anti-inflammatory action, and its efficacy in acne treatment 
has been proven. The most common side effects are local irritation, 
erythema, pruritus, burning and mild flaking, which tend to dis-
appear after four weeks of treatment.17-19 It can be indicated for the 
same clinical forms of acne and treatment conditions previously 
mentioned for topical retinoids, with the difference that use of aze-
laic acid does not present risks for pregnant and lactating women.5 
There is evidence from RCTs that associations between two 
topical drugs with different mechanisms of action are more effec-
tive in resolving acne than monotherapy.20-22 Topical presentations 
that combine two anti-acne agents (e.g. topical retinoid or BPO + 
topical antibiotic, or topical retinoid + BPO) are recommended as 
the first choice for treating mild to moderate papular or papulo-
pustular acne.1,5,20 Combinations of topical agents enhance treat-
ment adherence due to their convenience of dosage, especially 
for single-use daily presentations, and their faster onset of action. 
Moreover, due to their greater efficacy compared with topical 
monotherapy, they also promote greater improvement in quality 
of life for patients with mild to moderate acne vulgaris.22-25 
Oral medications for treating acne vulgaris are intended for use 
in moderate to severe cases or those that are refractory to topical 
medications.6,11,13 Oral antibiotics are among the agents of choice 
for severe cases of acne and moderate cases with inflammatory 
lesions affecting large areas of skin, especially the trunk. They can 
also be used in cases of mild to moderate inflammatory acne that 
fail to fully respond to topical therapy. They act by reducing bac-
terial colonization and inflammation in the affected follicles.1,4,5,12 
Despite their effectiveness in reducing the number of inflamma-
tory lesions, no oral antibiotic completely clears acne.6 
Oral antibiotics should always be used in association with topi-
cal retinoids, BPO, azelaic acid and/or antiandrogenic medications, 
in the case of women, due to the possibility of developing bacterial 
resistance. This issue becomes more important when oral antibiotics 
are administered for long periods and/or at low doses. Concomitant 
use of topical and oral antibiotics is contraindicated.1,5,26,27 
There is no conclusive evidence to show that any one antibi-
otic may be more effective than any other, even among the first 
and second generation tetracyclines that are the preferred oral 
antibiotic options for acne. However, among the tetracyclines, 
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minocycline has greater potential for adverse effects, and has 
higher cost.9,28,29 The choice of oral antibiotic should be based on 
the patient’s preference, pattern of adverse events and cost.6 
Combined oral contraceptives (COCs) suppress the activ-
ity of the sebaceous glands and reduce the formation of ovarian 
and adrenal androgens. Anti-androgen hormonal therapy with 
COCs should be used early in women with moderate to severe 
acne.1,3,5 There is good evidence, according to a Cochrane system-
atic review, that COCs do not differ much between each other with 
regard to their effectiveness in reducing inflammatory and non-
inflammatory facial lesions. However, it is not yet possible to say 
to what degree COCs are effective in treating acne when compared 
with other treatments.30 There is no evidence to show that spirono-
lactone is effective for treating acne, according to a Cochrane sys-
tematic review.31 None of the commercial preparations containing 
spironolactone currently available in Brazil or worldwide has been 
approved for use in treating acne. This is also the case with flu-
tamide, which has been proscribed for treating acne as a result of 
its adverse effects, especially acute liver failure.4,5 
Only oral isotretinoin has a mechanism of action that reaches 
all the pathogenic mechanisms relating to acne vulgaris. It is the 
most effective drug available against acne and promotes clini-
cal cure in 85% of the cases. Isotretinoin is indicated in severe 
cases that are resistant to other therapies, and for patients prone 
to scarring or whose acne has a significant psychosocial impact.1,5 
Consistent scientific evidence is still needed regarding its early 
use in mild cases, mainly because of the serious adverse effects 
related to isotretinoin. Such effects include teratogenicity and the 
possible risk of inflammatory bowel disease, depression and sui-
cide, which have not been confirmed by population studies.32-37 
There is good evidence in the literature that several treat-
ments using light sources can improve inflammatory acne over 
the short term, and that photodynamic therapy provides results 
that are more consistent than other such therapies. However, 
there is no consistent evidence regarding the long-term thera-
peutic response or in relation to conventional acne treatments.38,39 
Complementary and alternative treatments using herbs, aloe 
vera, pyridoxine, acids derived from fruits, tea tree oil, acupunc-
ture and moxibustion are still limited to empirical use. Further 
well-conducted clinical trials are needed for the efficacy and 
safety of alternative therapies to be adequately defined.6,40
CONCLUSION
A large number of commercial products are available for treat-
ing acne, among which several consist of combinations of differ-
ent drugs. It is recognized that, so far, there are insufficient com-
parative studies to generate good quality evidence with regard to 
the treatments available for treating acne. This may explain the 
differences that exist among international guidelines regarding 
treatment recommendations and may explain also why they are 
not fully grounded in consistent scientific evidence. With regard 
to some aspects of acne treatment, the guidelines are limited 
to the opinions of experts, many of whom declare potentially 
important conflicts of interest.
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